CN104208751A - Preparation method for novel kidney acellularized biological scaffold - Google Patents
Preparation method for novel kidney acellularized biological scaffold Download PDFInfo
- Publication number
- CN104208751A CN104208751A CN201410408131.3A CN201410408131A CN104208751A CN 104208751 A CN104208751 A CN 104208751A CN 201410408131 A CN201410408131 A CN 201410408131A CN 104208751 A CN104208751 A CN 104208751A
- Authority
- CN
- China
- Prior art keywords
- kidney
- preparation
- perfusion
- decellularized
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 8
- 230000010412 perfusion Effects 0.000 claims description 20
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 10
- 210000005084 renal tissue Anatomy 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000005429 filling process Methods 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 239000003599 detergent Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000001066 destructive effect Effects 0.000 abstract description 2
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
- 210000005239 tubule Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000001601 blood-air barrier Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002796 renal vein Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- -1 elastic fibers Proteins 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- FCZYGJBVLGLYQU-UHFFFAOYSA-M sodium;2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethanesulfonate Chemical compound [Na+].CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCS([O-])(=O)=O)C=C1 FCZYGJBVLGLYQU-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940073450 sudan red Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
一种新型肾脏去细胞生物支架的制备方法,不使用现有的常规使用的对支架结构有破坏作用的离子型去垢剂SDS,而采用含有碳酸钠的Triton-100溶液作为去垢剂,既不会产生离子型去垢剂SDS破坏支架结构的不良作用,且碳酸钠作为碱性物质,加入适量可增强去细胞的效果。
A preparation method of a novel kidney decellularized bioscaffold does not use the conventionally used ionic detergent SDS, which has a destructive effect on the scaffold structure, but uses Triton-100 solution containing sodium carbonate as the detergent. There will be no adverse effects of the ionic detergent SDS destroying the scaffold structure, and sodium carbonate, as an alkaline substance, can enhance the effect of decellularization by adding an appropriate amount.
Description
技术领域 technical field
本发明涉及器官组织去细胞化领域,具体涉及一种新型肾脏去细胞生物支架的制备方法。 The invention relates to the field of organ tissue decellularization, in particular to a preparation method of a novel kidney decellularized biological scaffold. the
背景技术 Background technique
组织工程支架材料是构建组织工程器官或组织的重要基础,细胞外基质(ECM)不仅是一种良好的生物支架,而且也是细胞重要的信号调节分子,能调控细胞的生长、代谢与分化。它具有原组织的宏观及微观结构,并且富含胶原、弹力纤维、层黏连蛋白、纤维连接蛋白等经去细胞后留下的细胞外基质成分。从不同组织获得的细胞外基质,包括皮肤、血管、神经、骨骼、肌腱、小肠黏膜下层、膀胱、心脏瓣膜等,已经在可再生材料应用中做了广泛研究。近年来,以ECM为支架材料的产品及去细胞技术已经应用于临床,包括人体皮肤、肠黏膜下层(SIS)、猪膀胱及猪心脏瓣膜等。随着组织工程的进展,对于整体脏器的去细胞技术也逐渐成为相关领域学者们研究的热点之一。0tt等采用小鼠离体心脏,经去细胞技术处理后保留心脏ECM,重新注入新生小鼠细胞,在体外培养后使心脏恢复了跳动,使体外再造具有生理活性的器官成为可能,这也给器官移植带来了新的希望。然而,由于肾脏的特殊结构及其复杂的功能,其细胞支架方面的研究还主要集中在人工合成支架上,鲜有关于全肾细胞外基质作为生物支架的报道。2009年我国刘春晓等通过去垢剂灌注法成功制备了大鼠全肾脱细胞外基质;2010年Nakayama等曾单纯用l%十二烷基硫酸钠(SDS)或1%曲拉通(Triton X-100)浸泡法制备出猕猴肾细胞外基质。目前国内外ECM的制备方法日趋成熟,主要有两大类:一是酶学法:常用的酶有胰蛋白酶、脱氧核糖核酸酶和核糖核酸酶;二是化学方法:常用的去垢剂有SDS、Triton X-100、Triton X-200、脱氧胆酸钠等。但是有研究报道,通常浓度(0.25%)的胰蛋白酶可水解胶原蛋白和弹力蛋白,破坏瓣膜支架结构。而去垢剂SDS则对支架结构有破坏作用。 Tissue engineering scaffold materials are an important basis for constructing tissue engineered organs or tissues. Extracellular matrix (ECM) is not only a good biological scaffold, but also an important signal regulator molecule for cells, which can regulate cell growth, metabolism and differentiation. It has the macroscopic and microscopic structure of the original tissue, and is rich in extracellular matrix components left after decellularization, such as collagen, elastic fibers, laminin, and fibronectin. Extracellular matrices obtained from different tissues, including skin, blood vessels, nerves, bones, tendons, small intestinal submucosa, bladder, heart valves, etc., have been extensively studied for renewable material applications. In recent years, products using ECM as a scaffold material and decellularization technology have been applied clinically, including human skin, intestinal submucosa (SIS), porcine bladder and porcine heart valves, etc. With the development of tissue engineering, the decellularization technology of whole organs has gradually become one of the research hotspots of scholars in related fields. Ott et al. used the isolated mouse heart to retain the ECM of the heart after decellularization technology, reinjected newborn mouse cells, and restored the beating of the heart after in vitro culture, making it possible to reconstruct physiologically active organs in vitro. Organ transplants offer new hope. However, due to the special structure and complex functions of the kidney, the research on its cell scaffolds is still mainly focused on artificially synthesized scaffolds, and there are few reports on the whole kidney extracellular matrix as a biological scaffold. In 2009, my country Liu Chunxiao et al. successfully prepared rat whole kidney acellular extracellular matrix by detergent perfusion; in 2010, Nakayama et al. used 1% sodium dodecyl sulfate (SDS) or 1% Triton X -100) soaking method to prepare extracellular matrix of macaque kidney. At present, the preparation methods of ECM at home and abroad are becoming more and more mature, and there are two main categories: one is enzymatic method: commonly used enzymes include trypsin, deoxyribonuclease and ribonuclease; the other is chemical method: commonly used detergents are SDS , Triton X-100, Triton X-200, sodium deoxycholate, etc. However, it has been reported that trypsin at a normal concentration (0.25%) can hydrolyze collagen and elastin, and destroy the structure of the valve stent. The detergent SDS has a destructive effect on the scaffold structure. the
发明内容 Contents of the invention
为了解决现有技术的缺点,本发明的提供了设计并合成一种新型肾脏去细胞生物支架的制备方法,通过含有碳酸钠的Triton-100溶液作为去垢剂,制备肾脏去细胞生物支架。 In order to solve the shortcomings of the prior art, the present invention provides a preparation method for designing and synthesizing a novel kidney decellularized bioscaffold, using Triton-100 solution containing sodium carbonate as a detergent to prepare the kidney decellularized bioscaffold. the
一种新型肾脏去细胞生物支架的制备方法,所述的制备方法包括以下步骤: A preparation method of a novel kidney decellularized bioscaffold, the preparation method comprising the following steps:
(1)在离体肾脏的动脉22G留置针插管,用肝素PBS冲洗肾内残留血液,至肾呈均一土黄色; (1) Intubate the artery of the isolated kidney with a 22G indwelling needle, and wash the residual blood in the kidney with heparin and PBS until the kidney is uniformly khaki;
(2)将整个肾脏组织在恒温37℃下依次灌注2000ml 0.1mol/L碳酸钠和1%溶解于PBS的Triton x-100混合溶液,以及500ml 的4%乙醇与0.01%过氧乙酸混合溶液,及含青、链霉素的PBS溶液,然后持续灌注,灌注的同时将肾组织浸泡于灌注液中,灌注速度均为15ml/min,灌注过程中观察肾脏颜色及形态的变化,待肾脏颜色变浅,由原来的土黄色变为白色并透明化。即得肾脏去细胞支架,将制得的肾脏去细胞支架保存于-80℃。 (2) Perfuse the whole kidney tissue with 2000ml 0.1mol/L sodium carbonate and 1% Triton x-100 mixed solution dissolved in PBS and 500ml mixed solution of 4% ethanol and 0.01% peracetic acid at a constant temperature of 37°C. And the PBS solution containing penicillin and streptomycin, and then continue to perfuse, soak the kidney tissue in the perfusion solution at the same time, the perfusion speed is 15ml/min, observe the changes in the color and shape of the kidney during the perfusion process, and wait until the color of the kidney changes. Light, from the original khaki to white and transparent. The kidney decellularized scaffold was obtained, and the prepared kidney decellularized scaffold was stored at -80°C.
所述的一种新型肾脏去细胞生物支架的制备方法,所述的步骤(2)中灌注时的灌注压为3.6mmHg。 In the preparation method of a novel kidney decellularized bioscaffold, the perfusion pressure during perfusion in the step (2) is 3.6 mmHg. the
所述的一种新型肾脏去细胞生物支架的制备方法,所述的步骤(2)中含青、链霉素的PBS溶液浓度为105 IU/L。 In the preparation method of a novel kidney decellularized bioscaffold, the concentration of the PBS solution containing penicillin and streptomycin in the step (2) is 105 IU/L. the
所述的一种新型肾脏去细胞生物支架的制备方法,所述的步骤(2)中灌注含青、链霉素的PBS溶液的灌注时间为8—10 h In the preparation method of a novel kidney decellularized bioscaffold, the infusion time of the PBS solution containing penicillin and streptomycin in the step (2) is 8-10 h
本发明的有益效果是:本发明提供了一种新型肾脏去细胞生物支架的制备方法,不使用现有的常规使用的对支架结构有破坏作用的离子型去垢剂SDS,而采用含有碳酸钠的Triton-100溶液作为去垢剂,既不会产生离子型去垢剂SDS破坏支架结构的不良作用,且碳酸钠作为碱性物质,加入适量可增强去细胞的效果。 The beneficial effect of the present invention is: the present invention provides a kind of preparation method of novel kidney decellularized bioscaffold, does not use the ionic detergent SDS that conventionally uses and has damaging effect to scaffold structure, but adopts the preparation method that contains sodium carbonate The Triton-100 solution of Triton-100 solution is used as a detergent, which will not cause the adverse effect of the ionic detergent SDS on destroying the scaffold structure, and sodium carbonate is used as an alkaline substance, adding an appropriate amount can enhance the effect of decellularization.
附图说明 Description of drawings
图1为本发明全肾的颜色及形态的变化图。 Fig. 1 is a graph showing changes in color and shape of the whole kidney of the present invention. the
图2为肾去细胞支架与对照组肾的透射电镜观察。 Figure 2 is the transmission electron microscope observation of the renal decellularized scaffold and the kidney of the control group. the
图3为肾去细胞支架与对照组肾的HE、PAS及Masson观察图。 Fig. 3 is the HE, PAS and Masson observation images of the renal decellularized scaffold and the kidney of the control group. the
图4为肾去细胞支架与对照组肾的蛋白免疫荧光分析图。 Fig. 4 is a picture of protein immunofluorescence analysis of renal decellularized scaffolds and kidneys of the control group. the
图5为体视显微镜下肾内血管的形态及分布图。 Figure 5 is a diagram showing the shape and distribution of blood vessels in the kidney under a stereo microscope. the
图2中1-足细胞,2-足突,3-基膜,4-血管内皮细胞,5-微绒毛,6-肾小管膜,7-线粒体,8-间质细胞,9-胶原纤维,10-肾小球囊,11-毛细血管膜,12-血管系膜。 In Figure 2, 1-podocytes, 2-foot processes, 3-basement membrane, 4-vascular endothelial cells, 5-microvilli, 6-tubular membrane, 7-mitochondria, 8-interstitial cells, 9-collagen fibers, 10- glomerulus, 11- capillary membrane, 12- mesangium. the
the
具体实施方式 Detailed ways
制备获取离体大鼠肾脏Preparation of isolated rat kidney
取健康成年SD大鼠,称重,按0.3—0.4ml/100g 10%水合氯醛行腹腔注射麻醉,起效后固定,打开腹腔,分离出下腔静脉,注射肝素钠溶液行全身肝素化处理。钝性分离双侧肾脏,可见肾呈棕红色,剥除肾的3层被膜,找到肾蒂,分离肾动、静脉和输尿管,离断输尿管,结扎肾动、静脉的起始处并离断,取肾,一侧肾进行灌注去细胞化处理,另一侧肾保存于-80℃作为对照组。 Take healthy adult SD rats, weigh them, anesthetize by intraperitoneal injection of 0.3-0.4ml/100g 10% chloral hydrate, fix them after the effect, open the abdominal cavity, separate the inferior vena cava, inject heparin sodium solution for whole-body heparinization . Bluntly dissect the bilateral kidneys, and the kidneys are brownish-red. Peel off the three layers of capsules of the kidneys, find the renal pedicle, separate the renal artery, vein and ureter, cut off the ureter, ligate and cut off the beginning of the renal artery and vein, Kidneys were taken, one side of the kidney was perfused and decellularized, and the other side of the kidney was stored at -80°C as a control group.
肾组织去细胞化Decellularization of kidney tissue
(1)将一侧肾组织保存于-80℃不做进一步处理作为对照组保存。 (1) One kidney tissue was stored at -80°C without further processing as a control group.
(2)肾去细胞组:将离体肾脏的动脉22G留置针插管,用肝素PBS冲洗肾内残留血液,至肾呈均一土黄色。将整个肾脏组织在恒温37℃下依次灌注2000ml 0.1mol/L碳酸钠和1%溶解于PBS的Triton x-100混合溶液,以及500ml 的4%乙醇与0.01%过氧乙酸混合溶液,及含青、链霉素的PBS溶液,灌注含青、链霉素的PBS溶液的灌注时间为8—10 h,含青、链霉素的PBS溶液浓度为105 IU/L,然后持续灌注,灌注的同时将肾组织浸泡于灌注液中,灌注时的灌注压为3.6mmHg,灌注速度均为15ml/min,灌注过程中观察肾脏颜色及形态的变化,待肾脏颜色变浅,由原来的土黄色变为白色并透明化。即得肾脏去细胞支架,将制得的肾脏去细胞支架保存于-80℃。 (2) Kidney decellularization group: the arterial 22G indwelling needle of the isolated kidney was intubated, and the residual blood in the kidney was washed with heparin and PBS until the kidney was uniformly khaki. Perfuse the whole kidney tissue with 2000ml 0.1mol/L sodium carbonate and 1% Triton x-100 mixed solution dissolved in PBS, and 500ml mixed solution of 4% ethanol and 0.01% peracetic acid at a constant temperature of 37°C, and cyanide containing The PBS solution containing penicillin and streptomycin, the perfusion time of the PBS solution containing penicillin and streptomycin is 8-10 h, the concentration of the PBS solution containing penicillin and streptomycin is 105 IU/L, and then the perfusion is continued. Soak the kidney tissue in the perfusion solution. The perfusion pressure during perfusion is 3.6mmHg, and the perfusion rate is 15ml/min. During the perfusion process, observe the changes in the color and shape of the kidney. White and transparent. The kidney decellularized scaffold was obtained, and the prepared kidney decellularized scaffold was stored at -80°C. the
肾组织去细胞化数据分析处理Renal tissue decellularization data analysis and processing
1、大体观察: 1. General observation:
观察新鲜肾及灌注加浸泡全过程中全肾的颜色及形态的变化,如图1所示:肾组织呈现由棕红色变为均一土黄色,在逐渐变为白色直至完全透明化为止。 Observe the changes in the color and shape of the fresh kidney and the whole kidney during the whole process of perfusion and immersion, as shown in Figure 1: the kidney tissue changes from brown-red to uniform khaki, and then gradually turns white until it is completely transparent.
2、基因组DNA含量分析: 2. Genomic DNA content analysis:
对照组的肾与去细胞组肾分别取皮质、髓质各50一80mg,经匀浆、细胞裂解,除蛋白,纯化后,提取基因组DNA(按照DNA试剂盒说明操作),紫外分光光度计测定其浓度后,并行琼脂糖凝胶电泳对其进行定性测定。 Take 50-80 mg of cortex and medulla from the kidney of the control group and the kidney of the decellularized group respectively, after homogenization, cell lysis, protein removal, and purification, genomic DNA is extracted (operated according to the instructions of the DNA kit), and measured by an ultraviolet spectrophotometer. After its concentration, parallel agarose gel electrophoresis for its qualitative determination.
结果如下表1所示: The results are shown in Table 1 below:
由表1可以看出 It can be seen from Table 1
对照组及去细胞组肾支架,行DNA检测,结果显示,对照组肾皮质内DNA平均含量为4.95×10-4 ng/L,髓质内DNA平均含量为3.48×10-4ng/L;去细胞组1肾皮质DNA平均含量为4.67×10-6ng/L,髓质内DNA平均含量为9.81×10-6ng/L,去细胞的比例均可高达97%以上。表明去细胞组DNA含量已大大降低。 The renal scaffolds of the control group and the decellularized group were tested for DNA. The results showed that the average DNA content in the renal cortex of the control group was 4.95×10 -4 ng/L, and the average DNA content in the medulla was 3.48×10 -4 ng/L; the average DNA content of renal cortex in decellularized group 1 was 4.67×10 -6 ng/L, the average DNA content in medulla was 9.81×10 -6 ng/L, and the proportion of decellularized cells could be as high as More than 97%. It shows that the DNA content of the decellularized group has been greatly reduced.
3、透射电镜观察: 3. Transmission electron microscope observation:
对照组及去细胞组肾,分别切成1.0ram3大小的组织块,在4℃2.5%戊二醛中固定12小时。经PBS冲洗后,锇酸固定,醋酸铀染色后,丙酮梯度脱水,环氧树脂包埋剂浸透,包埋,制作超薄切片,透射电镜下观察。 The kidneys of the control group and the decellularized group were cut into 1.0 mm3 tissue blocks respectively, and fixed in 2.5% glutaraldehyde at 4°C for 12 hours. After washing with PBS, fix with osmium acid, stain with uranyl acetate, dehydrate with gradient acetone, soak with epoxy resin embedding agent, embed, make ultra-thin sections, and observe under transmission electron microscope.
如图2所示: as shown in picture 2:
图2中 肾去细胞支架与对照组肾的透射电镜观察 Transmission electron microscope observation of kidney decellularized scaffold and control group kidney in Figure 2
A-C正常肾脏;D-F去细胞肾脏;图2中A中1为足细胞,2为足突,3为基膜,4为血管内皮细胞;图2中B中5为微绒毛,6为肾小管膜,7为线粒体;图2中C中8为间质细胞,9为胶原纤维;图2D中10为肾小球囊,11为毛细血管膜,12为血管系膜;图2中E中6为肾小管膜;图2中F中9为胶原纤维,6为肾小管膜,11为毛细血管膜。 A-C normal kidney; D-F decellularized kidney; in Figure 2 A, 1 is podocytes, 2 is foot process, 3 is basement membrane, 4 is vascular endothelial cells; in Figure 2 B, 5 is microvilli, 6 is tubular membrane , 7 is mitochondria; in Figure 2C, 8 is interstitial cells, and 9 is collagen fibers; in Figure 2D, 10 is glomerulus, 11 is capillary membrane, and 12 is mesangium; in Figure 2E, 6 is Renal tubule membrane; 9 in F in Fig. 2 is collagen fiber, 6 is renal tubule membrane, and 11 is capillary membrane.
对照组肾皮质可见肾小体结构完整、清晰,肾小体旁小管较致密,不易分辨;髓质部分可见大量管状样结构,管壁较厚者为近曲小管,管壁较薄者为远曲小管及集合管。去细胞组均可见肾小球、肾小管轮廓结构基本完整,基膜及纤维蛋白等细胞外基质组成的散在。“地图样”结构,管腔塌陷,中空而无细胞残留。 In the renal cortex of the control group, the structure of the renal corpuscle was complete and clear, and the tubules adjacent to the renal corpuscle were denser and difficult to distinguish; a large number of tubular structures were seen in the medulla, the thicker tubules were the proximal convoluted tubules, and the thinner tubules were the distal convoluted tubules. Tubules and collecting ducts. In the decellularized group, the outline structure of glomeruli and renal tubules was basically complete, and the extracellular matrix such as basement membrane and fibrin was scattered. "Geographic" structure, the lumen collapsed, hollow without cell residues. the
4、染色观察: 4. Dyeing observation:
图3为肾去细胞支架与对照组肾的HE、PAS及Masson观察 Figure 3 is the HE, PAS and Masson observations of the renal decellularized scaffolds and the kidneys of the control group
图3中上为正常肾脏;下为去细胞肾支架;正常肾脏内可见大量细胞存在;去细胞肾内无明显细胞残留,肾小球及肾小管结构完整,糖元成分及纤维充分保留。 In Figure 3, the top is the normal kidney; the bottom is the decellularized kidney scaffold; a large number of cells can be seen in the normal kidney; there is no obvious cell residue in the decellularized kidney, the structure of the glomeruli and renal tubules is intact, and the glycogen components and fibers are fully preserved.
5、免疫荧光检测: 5. Immunofluorescence detection:
对照组及去细胞组肾随机抽取各9张石蜡切片,免疫荧光检测胶原IV、LN及FN的表达,荧光显微镜下观察,胞核呈蓝色荧光,基膜上出现绿色荧光即为阳性表达。 Nine paraffin sections were randomly selected from the kidneys of the control group and the decellularized group. Immunofluorescence was used to detect the expression of collagen IV, LN and FN. Under the fluorescence microscope, the nuclei showed blue fluorescence and the basement membrane showed green fluorescence, indicating positive expression.
图4为 肾去细胞支架与对照组肾的蛋白免疫荧光分析 Figure 4 is the protein immunofluorescence analysis of renal decellularized scaffolds and kidneys of the control group
上:正常肾脏;下:去细胞肾支架;图中正常肾脏大量蓝染细胞核;去细胞肾基质内未见明显细胞核残留,胶原蛋白等充分保留。 Upper: normal kidney; lower: decellularized kidney scaffold; in the picture, a large number of blue-stained nuclei in the normal kidney; no obvious nucleus remains in the decellularized kidney matrix, and collagen is fully preserved.
6 、肾动脉血管铸型观察: 6. Observation of renal artery casts:
肾动脉灌注10%丙烯腈一丁二烯一苯乙烯树脂(ABS)苏丹红溶剂2~4ml,灌注时保持一定压力,流水冲洗冷却,50%盐酸腐蚀l一3d,清水冲洗干净,体视显微镜下观察肾内血管的形态及分布。 Perfuse the renal artery with 2-4ml of 10% acrylonitrile-butadiene-styrene resin (ABS) Sudan red solvent, maintain a certain pressure during perfusion, rinse and cool with running water, corrode with 50% hydrochloric acid for 1-3 days, rinse with clean water, and use a stereomicroscope Observe the shape and distribution of blood vessels in the kidney.
图5为体视显微镜下肾内血管的形态及分布图 Figure 5 is the morphology and distribution of intrarenal blood vessels under a stereo microscope
其中A是对照组肾,B是去细胞的肾,从图5可以看出去细胞组肾内血管呈“树枝样”分布,较稀疏,血管分支仍清晰可见,形态完整。 Among them, A is the kidney of the control group, and B is the decellularized kidney. It can be seen from Figure 5 that the blood vessels in the decellularized group are distributed in a "branch-like" manner, which is relatively sparse, and the branches of the blood vessels are still clearly visible and the shape is complete.
本实施例的肾脏去细胞生物支架的制备方法还可用于制备人或其他动物的肾脏去细胞生物支架,如尸肾,猪肾,猴肾等。 The preparation method of the kidney decellularized bioscaffold in this embodiment can also be used to prepare human or other animal kidney decellularized bioscaffolds, such as cadaveric kidney, pig kidney, monkey kidney, etc. the
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410408131.3A CN104208751A (en) | 2014-08-19 | 2014-08-19 | Preparation method for novel kidney acellularized biological scaffold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410408131.3A CN104208751A (en) | 2014-08-19 | 2014-08-19 | Preparation method for novel kidney acellularized biological scaffold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104208751A true CN104208751A (en) | 2014-12-17 |
Family
ID=52090916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410408131.3A Pending CN104208751A (en) | 2014-08-19 | 2014-08-19 | Preparation method for novel kidney acellularized biological scaffold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208751A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104841017A (en) * | 2015-05-28 | 2015-08-19 | 四川大学华西医院 | A decellularized liver bioscaffold with anticoagulant properties and preparation method thereof |
| CN105031731A (en) * | 2015-08-18 | 2015-11-11 | 温州医科大学 | Preparation method of rapidly decellularized unifoliate liver biological scaffold |
| CN114214284A (en) * | 2021-12-31 | 2022-03-22 | 四川大学华西医院 | Method for culturing kidney tumor organoid |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| CN101272815A (en) * | 2005-08-26 | 2008-09-24 | 明尼苏达大学董事会 | Decellularization and recellularization of organs and tissues |
| CN101850136A (en) * | 2010-06-11 | 2010-10-06 | 四川大学华西医院 | An implantable bioartificial liver |
| CN103272278A (en) * | 2013-05-28 | 2013-09-04 | 北京博辉瑞进生物科技有限公司 | Method for preparing animal derived implantable medical biomaterial |
| CN103458935A (en) * | 2010-09-01 | 2013-12-18 | 明尼苏达大学董事会 | Methods of recellularizing a tissue or organ for improved transplantability |
| CN103636596A (en) * | 2013-11-29 | 2014-03-19 | 东方康瑞(北京)科技发展有限责任公司 | Bio-membrane protective solution as well as preparation and application thereof |
| CN103861151A (en) * | 2014-03-27 | 2014-06-18 | 成都青山利康药业有限公司 | Method for preparing acellular placenta substrate material |
-
2014
- 2014-08-19 CN CN201410408131.3A patent/CN104208751A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| CN101272815A (en) * | 2005-08-26 | 2008-09-24 | 明尼苏达大学董事会 | Decellularization and recellularization of organs and tissues |
| CN101850136A (en) * | 2010-06-11 | 2010-10-06 | 四川大学华西医院 | An implantable bioartificial liver |
| CN103458935A (en) * | 2010-09-01 | 2013-12-18 | 明尼苏达大学董事会 | Methods of recellularizing a tissue or organ for improved transplantability |
| CN103272278A (en) * | 2013-05-28 | 2013-09-04 | 北京博辉瑞进生物科技有限公司 | Method for preparing animal derived implantable medical biomaterial |
| CN103636596A (en) * | 2013-11-29 | 2014-03-19 | 东方康瑞(北京)科技发展有限责任公司 | Bio-membrane protective solution as well as preparation and application thereof |
| CN103861151A (en) * | 2014-03-27 | 2014-06-18 | 成都青山利康药业有限公司 | Method for preparing acellular placenta substrate material |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104841017A (en) * | 2015-05-28 | 2015-08-19 | 四川大学华西医院 | A decellularized liver bioscaffold with anticoagulant properties and preparation method thereof |
| CN104841017B (en) * | 2015-05-28 | 2017-06-13 | 四川大学华西医院 | A decellularized liver bioscaffold with anticoagulant properties and preparation method thereof |
| CN105031731A (en) * | 2015-08-18 | 2015-11-11 | 温州医科大学 | Preparation method of rapidly decellularized unifoliate liver biological scaffold |
| CN114214284A (en) * | 2021-12-31 | 2022-03-22 | 四川大学华西医院 | Method for culturing kidney tumor organoid |
| CN114214284B (en) * | 2021-12-31 | 2024-01-26 | 四川大学华西医院 | A method of culturing renal tumor organoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adamski et al. | Two methods for decellularization of plant tissues for tissue engineering applications | |
| Liang et al. | Perfusable adipose decellularized extracellular matrix biological scaffold co-recellularized with adipose-derived stem cells and L6 promotes functional skeletal muscle regeneration following volumetric muscle loss | |
| CN112546302B (en) | Human liver scaffold | |
| CN104288838B (en) | Kit for obtaining multiple-organ and tissue extracellular matrix and using method of kit | |
| CN105797212A (en) | Preparing method and application of acellular amniotic membrane used for repairing skin wound difficult to heal | |
| Li et al. | Preparation and characterization of a novel acellular swim bladder as dura mater substitute | |
| CN112915264A (en) | Preparation method for gelatin-sodium alginate-PRP composite material | |
| CN118370871B (en) | A method for preparing decellularized biological omentum and decellularized biological omentum prepared thereby | |
| WO2010139209A1 (en) | Kit used for obtaining whole liver scaffold and method for obtaining whole liver scaffold | |
| Hochman-Mendez et al. | Restoring anatomical complexity of a left ventricle wall as a step toward bioengineering a human heart with human induced pluripotent stem cell-derived cardiac cells | |
| CN112870445A (en) | Preparation method and application of soft tissue repair material | |
| CN115137881A (en) | Three-layer bionic artificial blood vessel with antithrombotic and tissue regeneration promoting functions and preparation method thereof | |
| CN104208751A (en) | Preparation method for novel kidney acellularized biological scaffold | |
| CN104511052A (en) | Culture method for composition of periosteal biological scaffold and allogenic seed cells | |
| CN102697581B (en) | Method for constructing tissue engineering blood vessel | |
| CN108969466A (en) | A kind of facial mask and preparation method thereof of preserving youthful looks based on the umbilical cord mesenchymal stem cells secretion activity factor | |
| RU2653489C2 (en) | Method for obtaining decellularized matrices of parenchymal organs of laboratory animals | |
| CN119732903A (en) | A composition, preparation method and application of umbilical cord mesenchymal stem cell exosomes combined with GPT hydrogel | |
| CN106606512A (en) | Mixed cell preparation used for treating myocardial infarction as well as preparation method thereof and application thereof | |
| CN105031731B (en) | A kind of quick preparation method for removing cell list leaf liver biological support | |
| CN105497983A (en) | Simple and efficient preparation method of stem cell patch | |
| CN105194736A (en) | Preparation method of accellular brain tissue three-dimensional scaffold | |
| CN116868962A (en) | A method for constructing an osteosarcoma PDX tumor model based on fish skin decellularized scaffold | |
| CN107281551A (en) | The method that freezing method prepares liver biological support | |
| Gullabzada et al. | A Systematic Review of Tissue Engineering of a Total Artificial Heart: Focus on Perfusion Decellularization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141217 |